Side effect management of Lazertinib requires targeted measures based on specific reaction types, with key focus on the prevention and control of venous thromboembolism, skin reactions, and ocular toxicity.

Prevention and Management of Venous Thromboembolism

Prophylactic anticoagulation is mandatory for the first 4 months of treatment (vitamin K antagonists should be avoided).

Monitor for symptoms including lower extremity swelling and chest pain.

The incidence is up to 36%. If venous thromboembolism occurs, treatment must be interrupted and managed medically.

Management of Skin Reactions

(1) Preventive Measures

Use alcohol-free emollients and maintain full sun protection throughout treatment.

Rash occurs in 86% of patients. Prophylactic oral antibiotics are recommended to reduce infection risk.

(2) Graded Management

Grade 1 rash: continue treatment

Grade 2: interrupt treatment and use topical corticosteroids

Grade 3 or higher: permanent discontinuation

Management of Ocular Toxicity

Ocular reactions such as keratitis occur in 16% of patients.

Immediate referral to an ophthalmologist is required.

Treatment may continue in mild‑to‑moderate cases, but permanent discontinuation is mandatory for severe cases.

Relief of Gastrointestinal Reactions

Nausea, diarrhea, etc., may resolve spontaneously.

Dose adjustment is required in severe cases:

First reduction to 160 mg once daily

Second reduction to 80 mg once daily

Special Precautions

Interstitial lung disease (incidence 3.1%) requires immediate and permanent discontinuation.

Baseline liver function assessment is required for all patients before treatment.

No dose adjustment is needed in mild‑to‑moderate hepatic impairment.